Dev Chatterjee, Raghavendra Kamath, Sohini Das &Amp;Amp; Avishek Rakshit

Stories by Dev Chatterjee, Raghavendra Kamath, Sohini Das &Amp;Amp; Avishek Rakshit

Covid-19: Zero cash flows force India Inc to sell assets

Covid-19: Zero cash flows force India Inc to sell assets

Rediff.com   22 Oct 2020

Not just mid- and small-sized firms, even big ones will either sell group companies or stakes in their listed entities to tide over crisis; more sell-offs seen in coming months.

Singapore's Mapletree Investments buys land in Mumbai for Rs 525 crore

Singapore's Mapletree Investments buys land in Mumbai for Rs 525 crore

Rediff.com   12 Oct 2020

The Kanakia group, from which Mapletree did the purchase, had bought the plot from India Tube Mills and Metal Industries for Rs 363 crore in 2018.

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com   10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.

Will PNB acquire beleaguered Lakshmi Vilas Bank?

Will PNB acquire beleaguered Lakshmi Vilas Bank?

Rediff.com   8 Oct 2020

PNB has rich experience in the integration of commercial banks.

Fuelled by demand in southern markets, office leasing rises

Fuelled by demand in southern markets, office leasing rises

Rediff.com   6 Oct 2020

The Q3 office rebound growth was led by Bengaluru and Hyderabad, which together accounted for nearly 80 per cent of the net absorption in Q3.

Covaxin: How Bharat Biotech plans to boost immunity

Covaxin: How Bharat Biotech plans to boost immunity

Rediff.com   6 Oct 2020

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Rediff.com   6 Oct 2020

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.

Covid vaccine: Pharma firms ready expansion plans

Covid vaccine: Pharma firms ready expansion plans

Rediff.com   6 Oct 2020

The Indian vaccine industry largely feels there are two ways in which vaccine innovation can be spurred - one, get a high price for the product and two, have the government buy a few hundred million doses of the product at a certain price.

SBI Caps, JM Financial to sell Reliance Capital assets

SBI Caps, JM Financial to sell Reliance Capital assets

Rediff.com   2 Oct 2020

The key assets put on the block include its entire stake in Reliance General Insurance Company, the third-largest private sector insurer, and a 49 per cent stake in Reliance Nippon Life Insurance, a joint venture with Nippon Life, which is among the top five private-sector insurance companies.

How India is gearing up to distribute Covid-19 vaccine

How India is gearing up to distribute Covid-19 vaccine

Rediff.com   18 Sep 2020

A model being considered is to have a combined cold chain approach - where the agricultural cold chain would be combined with vaccine cold chains.

Labs bet on Covid tests for next growth phase

Labs bet on Covid tests for next growth phase

Rediff.com   14 Sep 2020

The bouquet of Covid-19 tests that most diagnostic labs are offering include antibody tests (blood tests), rapid antigen tests (point of care tests that detect the presence of an antigen from a nasal or throat swab in case of SARS-CoV-2), and reverse transcription-polymerase chain reaction (RT-PCR) tests.

India will wait for DCGI nod to restart Oxford vaccine trial

India will wait for DCGI nod to restart Oxford vaccine trial

Rediff.com   11 Sep 2020

The global trials were halted after a study participant suffered a 'potentially unexplained illness, reports Sohini Das.

The real story behind Adani-Mumbai Airport deal

The real story behind Adani-Mumbai Airport deal

Rediff.com   8 Sep 2020

What made the tide turn in favour of the Adani group was the Covid-19 pandemic, which shut down airports the world over, including Mumbai. There was no cash flow and the firm started defaulting on salaries July onwards.

With coronavirus still around, 'virus killers' hit the market

With coronavirus still around, 'virus killers' hit the market

Rediff.com   7 Sep 2020

A gamechanger for offices and factories, Shycocan, claims to be able to clear an area of 1000 square feet from coronavirus.

Govt banks to invoke personal guarantee of defaulters

Govt banks to invoke personal guarantee of defaulters

Rediff.com   5 Sep 2020

Finance ministry advises banks to invoke personal guarantees of all promoters whose companies have gone to NCLT for debt resolution.

In the works: Priority list of who will get Covid vaccine first

In the works: Priority list of who will get Covid vaccine first

Rediff.com   4 Sep 2020

The Centre has also contacted five domestic and three multinational vaccine makers to understand how soon a candidate vaccine against Covid-19 will be ready.

Indian pharma firms working on new repurposed drug for Covid-19

Indian pharma firms working on new repurposed drug for Covid-19

Rediff.com   2 Sep 2020

Many companies globally are working on plasma research to develop and manufacture hyperimmune globulin therapies from plasma donations.

RBI rejects BoB's plan to send Anil Ambani firms to NCLT

RBI rejects BoB's plan to send Anil Ambani firms to NCLT

Rediff.com   31 Aug 2020

The RBI rejection is a second blow to BoB - the lead bank of both companies -- after a Delhi high court order on August 18 stayed a move by BoB and the entire consortium of lenders to classify these accounts as fraud, restraining them from taking any other coercive action till the next hearing.

Biyani's Future board to meet on Sep 7 to decide on RIL offer

Biyani's Future board to meet on Sep 7 to decide on RIL offer

Rediff.com   29 Aug 2020

According to the plan made by the lenders and RIL, all Future group listed companies will be merged into Future Enterprises. RIL will then invest Rs 8,500 crore in the merged entity which will include the retail business.

Pandemic brings windfall for e-pharma companies

Pandemic brings windfall for e-pharma companies

Rediff.com   27 Aug 2020

The online pharmacy market, which was worth about $512 million in 2018, is growing at a CAGR of 63 per cent and is expected to hit overall revenues of over $3.6 billion by 2022.